We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 358

Swearing Behind A Reference With Reasonably Continuous Diligence
  • Foley & Lardner LLP
  • USA
  • November 16 2016

In Perfect Surgical Techniques, Inc. v. Olympus America, Inc., the Federal Circuit vacated and remanded a USPTO Patent Trial and Appeal Board


District Court Denies Extra Patent Term Adjustment When National Stage Entry Date Falls On A Holiday
  • Foley & Lardner LLP
  • USA
  • October 27 2016

Some patent term adjustment (PTA) cases have broad impact-like Wyeth v. Kappos and Novartis v. Lee-but Acetelion Pharmaceuticals, Inc. v. Lee


Pinpointing invention conception date in a patent interference
  • Foley & Lardner LLP
  • USA
  • April 9 2013

In Dawson v. Dawson, the Federal Circuit considered an unusual case with a question that often arises in interferences: when did the inventor invent


The PRICED Act Would Expedite Biosimilar Market Entry
  • Foley & Lardner LLP
  • USA
  • July 12 2016

Although the 12-year exclusivity period for original biologic products was a heavily negotiated provision of the Biologics Price Competition and


Janssen Seeks Injunction Against Remicade Biosimilar Based On Cell Culture Patent
  • Foley & Lardner LLP
  • USA
  • July 14 2016

In a complaint filed June 14, 2016, Janssen Biotech Inc. seeks a preliminary injunction that would bar Celltrion and Hospira from selling the


PTAB Upholds Lialda Patent Over Kyle Bass IPR Challenge
  • Foley & Lardner LLP
  • USA
  • October 11 2016

The USPTO Patent Trial and Appeal Board (PTAB) has issued a Final Written Decision upholding Shire’s Lialda patent over the Inter Partes Review


Divided infringement between doctor and patient
  • Foley & Lardner LLP
  • USA
  • October 1 2015

Recent jurisprudence on the issue of divided infringement has arisen in the context of computer-related Technologies, where a user or customer


Patent Term Adjustment Versus Double Patenting
  • Foley & Lardner LLP
  • USA
  • February 25 2016

In Magna Electronics, Inc. v. TRW Automotive Holdings Corp., No. 1:12-cv-654; 1:13-cv-324 (Dec. 10, 2015), Judge Maloney of the U.S. District Court


Obviousness versus obviousness-type double patenting
  • Foley & Lardner LLP
  • USA
  • November 24 2015

In Prometheus Laboratories, Inc. v. Roxane Laboratories, Inc., the Federal Circuit affirmed the district court's finding that Prometheus' claims were


Judge Grants Gilead Motion To Invalidate Remicade Patent For Obviousness-Type Double Patenting
  • Foley & Lardner LLP
  • USA
  • October 5 2016

The FDA approved Inflectra-Celltrion’s biosimilar version of Janssen’s Remicade (infliximab) product-in April 2016, but according to Pfizer’s press